Radiolabeling and Cell Binding Studies of Lamivudine for Lung Cancer Diagnosis

Creative Commons License

Ekinci M., Öztürk A. A., İlem Özdemir D.

8th International Medicine and Health Sciences Researches Congress, İstanbul, Turkey, 25 - 26 December 2021, vol.1, pp.80-81

  • Publication Type: Conference Paper / Summary Text
  • Volume: 1
  • City: İstanbul
  • Country: Turkey
  • Page Numbers: pp.80-81
  • Anadolu University Affiliated: Yes


Cancer is one of the leading causes of death in the world. Among the top 10 cancer types, trachea, bronchial, and lung cancers are the most common cancer in men and the fifth most common cancer in women. The application of imaging techniques is critical in the early detection of cancer. The goal of this research is to develop a novel radiopharmaceutical that could detect lung cancer. In the present study, Lamivudine (LAM) was radiolabeled with 99mTc, and the radiochemical purity (RP) of [99mTc]Tc-LAM was measured using Radio-Thin Layer Chromatography (RTLC) and found to be≥97% up to 6 h. The highest RP was achieved with 7.5 mg LAM, 150 μg stannous chloride, 0.750 mg ascorbic acid and 37 MBq [99mTc]NaTcO4- at pH 7.4 at room temperature for 15 min incubation time.At 120 min, [99mTc]Tc-LAM bounded to A-549 (lung cancer cell line) cells (32.71±1.64%) at a rate more than 6 times higher than the L-929 (fibroblast cell line) cells (5.02±0.25%). The findings showed that the newly developed [99mTc]Tc-LAM has potential features for lung cancer detection.

Keywords: Lamivudine; Technetium-99m; Radiolabeling; 99mtc-Lamivudine, Lung Cancer Diagnosis, Cell Binding.